<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01232504</url>
  </required_header>
  <id_info>
    <org_study_id>L-09-01</org_study_id>
    <nct_id>NCT01232504</nct_id>
  </id_info>
  <brief_title>Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCT</brief_title>
  <official_title>Effect of Granulocyte-macrophage Stimulating Factor on Prevention and Treatment of Invasive Fungal Diseases in the Recipients of Allogeneic Stem Cell Transplantation: A Prospective Multicenter Randomized Phase 4 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiamen Amoytop Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Jiao Tong University Affiliated First People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xiamen Amoytop Biotech Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We conducted a prospective, multicenter, open-label randomized trial to compare the
      antifungal effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF),
      Recombinant Human Granulocyte Stimulating Factor (rhG-CSF) or a combination of rhGM-CSF and
      rhG-CSF for neutropenic patients undergoing allogeneic stem cell transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      From Sept 2009 to Dec 2012, we recruited consecutive patients with hematological diseases
      undergoing allogeneic stem cell transplantation at 5 institutions in China. Recipients
      between ages of 14 to 60 years old were eligible. Eligible patients were randomized to
      receive once daily subcutaneous 5-7μg/kg/d GM-CSF (Molgramostim, TOPLEUCON®; Xiamen Amoytop
      Biotech Co., Ltd., China) (GM-CSF group), 5-7μg/kg/d G-CSF (G-CSF group), or a combination of
      2-3μg/kg/d GM-CSF and 2-3μg/kg/d G-CSF each (G-CSF+GM-CSF group). Administration of CSFs was
      started on day 5 post-transplant and continued until recovery from neutropenia (absolute
      neutrophil count [ANC] &gt; 1.5×10(9)/L for 2 consecutive days). If absolute neutrophil count
      (ANC) decreased to &lt; 1.5×10(9)/L within 5 days after withdrawal of CSFs, the same CSF would
      be resumed until the absolute neutrophil count (ANC) reached 1.5×10(9)/L again. All patients
      received antimicrobial prophylaxis with oral levofloxacin 500 mg daily and antifungal
      prophylaxis with oral fluconazole 200 mg daily.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidences of Invasive Fungal Diseases (IFD)</measure>
    <time_frame>100 day post transplant</time_frame>
    <description>The incidence of proven and probable Invasive fungal diseases (IFD) within 100 days post transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hematological Engraftment</measure>
    <time_frame>100 days post transplant</time_frame>
    <description>The median time of neutrophil and platelet recovery .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant Related Mortality</measure>
    <time_frame>100 days post transplant</time_frame>
    <description>Transplant related mortality within 100 days after Allogeneic Stem Cell Transplantation (Allo-HSCT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Ⅱ- Ⅳ Acute Graft Versus Host Disease (aGVHD)</measure>
    <time_frame>100 days post transplant</time_frame>
    <description>Incidence of Ⅱ- Ⅳacute graft versus host disease (aGVHD) within 100 days after allogeneic stem cell transplantation (Allo-HSCT).The severity of acute GVHD in the three main target organs (skin, liver, gastrointestinal tract) was assigned stage 1 to 4 based on accepted criteria (Consensus Conference on Acute GVHD Grading).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IFD Related Mortality</measure>
    <time_frame>3-1099 days</time_frame>
    <description>IFD-related mortalities after a median follow-up of 600 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse Related Mortality</measure>
    <time_frame>3～1099 days</time_frame>
    <description>Relapse related mortality after a median follow-up of 600 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft Versus Host Disease (aGVHD) Related Mortality</measure>
    <time_frame>3-1099 days</time_frame>
    <description>Graft versus host disease (aGVHD) related mortality after a median follow-up of 600 days .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemorrhage Related Mortality</measure>
    <time_frame>3-1099 days</time_frame>
    <description>Hemorrhage related mortality after a median follow-up of 600 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection Related Mortality</measure>
    <time_frame>3～1099 days)</time_frame>
    <description>Infection related mortality after a median follow-up of 600 days.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">206</enrollment>
  <condition>Mycoses</condition>
  <arm_group>
    <arm_group_label>rhGM-CSF group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subcutaneous 5-7μg/kg/d Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rhG-CSF+rhGM-CSF group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a combination of 2-3μg/kg/d Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) and 2-3μg/kg/d Recombinant Human Granulocyte Stimulating Factor (rhG-CSF) each</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rhG-CSF group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subcutaneous 5-7μg/kg/d Recombinant Human Granulocyte Stimulating Factor (rhG-CSF) once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhGM-CSF group</intervention_name>
    <description>subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] &gt; 1.5×10(9)/L for 2 consecutive days).</description>
    <arm_group_label>rhGM-CSF group</arm_group_label>
    <other_name>Topleucon®</other_name>
    <other_name>Granulocyte Macrophage Colony Stimulating Factor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhG-CSF+rhGM-CSF group</intervention_name>
    <description>a combination of 2-3μg/kg/d rhGM-CSF and 2-3μg/kg/d rhG-CSF each after transplantation, started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] &gt; 1.5×10(9)/L for 2 consecutive days).</description>
    <arm_group_label>rhG-CSF+rhGM-CSF group</arm_group_label>
    <other_name>Topleucon®</other_name>
    <other_name>Granulocyte Macrophage Colony Stimulating Factor</other_name>
    <other_name>Granulocyte Colony Stimulating Factor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhG-CSF group</intervention_name>
    <description>subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] &gt; 1.5×10(9)/L for 2 consecutive days).</description>
    <arm_group_label>rhG-CSF group</arm_group_label>
    <other_name>Granulocyte Colony Stimulating Factor</other_name>
    <other_name>Topleucon®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 14~60 years old

          -  Allogenic hematological stem cell transplantation(HSCT) patients.

          -  Cardiac ejection factor ≥ normal upper limit, Aspartate aminotransferase and/or
             Alanine aminotransferase &lt; 2 upper limit of normal, and/or total bilirubin &lt; 2.5 upper
             limit of normal, creatinine &lt; upper limit of normal.

          -  Informed consent.

        Exclusion Criteria:

          -  Evidence of proven, probable or possible fungal infection at the time of enrollment.

          -  Patients were receiving anti-fungal treatment with proven SFI before transplantation.

          -  A history of hypersensitivity to G-CSF or GM-CSF.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chun Wang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuhan Tongji Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai First People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xinjiang Medical University</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <zip>830054</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2010</study_first_submitted>
  <study_first_submitted_qc>October 31, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2010</study_first_posted>
  <results_first_submitted>January 26, 2014</results_first_submitted>
  <results_first_submitted_qc>October 22, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 27, 2014</results_first_posted>
  <last_update_submitted>October 27, 2014</last_update_submitted>
  <last_update_submitted_qc>October 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allo-HSCT</keyword>
  <keyword>rhGM-CSF</keyword>
  <keyword>Systemic fungal infection (SFI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>rhGM-CSF Group</title>
          <description>subcutaneous recombinant human granulocyte-macrophage stimulating factor (rhGM-CSF) 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] &gt; 1.5×10(9)/L for 2 consecutive days).</description>
        </group>
        <group group_id="P2">
          <title>rhG-CSF+ rhGM-CSF Group</title>
          <description>a combination of 2-3μg/kg/d recombinant human granulocyte-macrophage stimulating factor (rhGM-CSF) and 2-3μg/kg/d recombinant human granulocyte stimulating factor (rhG-CSF) each after transplantation, started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] &gt; 1.5×10(9)/L for 2 consecutive days).</description>
        </group>
        <group group_id="P3">
          <title>rhG-CSF Group</title>
          <description>subcutaneous recombinant human granulocyte stimulating factor (rhGM-CSF) 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] &gt; 1.5×10(9)/L for 2 consecutive days).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="69"/>
                <participants group_id="P3" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="67"/>
                <participants group_id="P3" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>rhGM-CSF Group</title>
          <description>subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] &gt; 1.5×10(9)/L for 2 consecutive days).</description>
        </group>
        <group group_id="B2">
          <title>rhG-CSF+ rhGM-CSF Group</title>
          <description>a combination of 2-3μg/kg/d rhGM-CSF and 2-3μg/kg/d rhG-CSF each after transplantation, started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] &gt; 1.5×10(9)/L for 2 consecutive days).</description>
        </group>
        <group group_id="B3">
          <title>rhG-CSF Group</title>
          <description>subcutaneous rhG-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] &gt; 1.5×10(9)/L for 2 consecutive days).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="68"/>
            <count group_id="B2" value="69"/>
            <count group_id="B3" value="69"/>
            <count group_id="B4" value="206"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.68" lower_limit="14" upper_limit="60"/>
                    <measurement group_id="B2" value="32.55" lower_limit="14" upper_limit="56"/>
                    <measurement group_id="B3" value="32.04" lower_limit="15" upper_limit="53"/>
                    <measurement group_id="B4" value="31.75" lower_limit="14" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Hematological Engraftment</title>
        <description>The median time of neutrophil and platelet recovery .</description>
        <time_frame>100 days post transplant</time_frame>
        <population>The number of intention-to-treat patients is 206. The hematological engraftment analysis within 100 day is based on intention-to-treat (ITT)patients .</population>
        <group_list>
          <group group_id="O1">
            <title>rhGM-CSF Group</title>
            <description>subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] &gt; 1.5×10(9)/L for 2 consecutive days).</description>
          </group>
          <group group_id="O2">
            <title>rhG-CSF + rhGM-CSF Group</title>
            <description>a combination of 2-3μg/kg/d rhGM-CSF and 2-3μg/kg/d rhG-CSF each after transplantation, started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] &gt; 1.5×10(9)/L for 2 consecutive days).</description>
          </group>
          <group group_id="O3">
            <title>rhG-CSF Group</title>
            <description>subcutaneous rhG-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] &gt; 1.5×10(9)/L for 2 consecutive days).</description>
          </group>
        </group_list>
        <measure>
          <title>Hematological Engraftment</title>
          <description>The median time of neutrophil and platelet recovery .</description>
          <population>The number of intention-to-treat patients is 206. The hematological engraftment analysis within 100 day is based on intention-to-treat (ITT)patients .</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Median time for neutrophil recovery to 0.5×10(9)/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="9" upper_limit="25"/>
                    <measurement group_id="O2" value="11" lower_limit="5" upper_limit="28"/>
                    <measurement group_id="O3" value="11" lower_limit="6" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median time for platelet recovery to 50 × 10(9)/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="10" upper_limit="200"/>
                    <measurement group_id="O2" value="19" lower_limit="10" upper_limit="200"/>
                    <measurement group_id="O3" value="25" lower_limit="12" upper_limit="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transplant Related Mortality</title>
        <description>Transplant related mortality within 100 days after Allogeneic Stem Cell Transplantation (Allo-HSCT).</description>
        <time_frame>100 days post transplant</time_frame>
        <population>The number of intention-to-treat patients is 206. The transplant related mortality analysis within 100 day is based on intention-to-treat (ITT) patients .</population>
        <group_list>
          <group group_id="O1">
            <title>rhGM-CSF Group</title>
            <description>subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] &gt; 1.5×10(9)/L for 2 consecutive days).</description>
          </group>
          <group group_id="O2">
            <title>rhG-CSF+ rhGM-CSF Group</title>
            <description>a combination of 2-3μg/kg/d rhGM-CSF and 2-3μg/kg/d rhG-CSF each after transplantation, started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] &gt; 1.5×10(9)/L for 2 consecutive days).</description>
          </group>
          <group group_id="O3">
            <title>rhG-CSF Group</title>
            <description>subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] &gt; 1.5×10(9)/L for 2 consecutive days).</description>
          </group>
        </group_list>
        <measure>
          <title>Transplant Related Mortality</title>
          <description>Transplant related mortality within 100 days after Allogeneic Stem Cell Transplantation (Allo-HSCT).</description>
          <population>The number of intention-to-treat patients is 206. The transplant related mortality analysis within 100 day is based on intention-to-treat (ITT) patients .</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" lower_limit="3.3" upper_limit="18.2"/>
                    <measurement group_id="O2" value="8.7" lower_limit="3.3" upper_limit="17.9"/>
                    <measurement group_id="O3" value="21.7" lower_limit="12.7" upper_limit="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Ⅱ- Ⅳ Acute Graft Versus Host Disease (aGVHD)</title>
        <description>Incidence of Ⅱ- Ⅳacute graft versus host disease (aGVHD) within 100 days after allogeneic stem cell transplantation (Allo-HSCT).The severity of acute GVHD in the three main target organs (skin, liver, gastrointestinal tract) was assigned stage 1 to 4 based on accepted criteria (Consensus Conference on Acute GVHD Grading).</description>
        <time_frame>100 days post transplant</time_frame>
        <population>The number of intention-to-treat patients is 206. The incidence of aGVHD analysis is based on intention-to-treat (ITT) patients .</population>
        <group_list>
          <group group_id="O1">
            <title>rhGM-CSF</title>
            <description>5-7μg/kg per day
rhGM-CSF: 5-7μg/kg daily subcutaneously（sc）without interruption until neutrophils≥1.5×10(9)/L for two continuous days,starting 5 days after transplantation.</description>
          </group>
          <group group_id="O2">
            <title>rhGM-CSF Plus rhG-CSF</title>
            <description>rhGM-CSF and rhG-CSF both at 2-3μg/kg per day
rhGM-CSF plus rhG-CSF: rhGM-CSF and rhG-CSF (both at 2-3μg/kg/d) subcutaneously（sc）without interruption until neutrophils≥1.5×10(9)/L for two continuous days,starting 5 days after transplantation.</description>
          </group>
          <group group_id="O3">
            <title>rhG-CSF</title>
            <description>5-7μg/kg per day
rhG-CSF: 5-7μg/kg daily subcutaneously（sc）without interruption until neutrophils≥1.5×10(9)/L for two continuous days,starting 5 days after transplantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Ⅱ- Ⅳ Acute Graft Versus Host Disease (aGVHD)</title>
          <description>Incidence of Ⅱ- Ⅳacute graft versus host disease (aGVHD) within 100 days after allogeneic stem cell transplantation (Allo-HSCT).The severity of acute GVHD in the three main target organs (skin, liver, gastrointestinal tract) was assigned stage 1 to 4 based on accepted criteria (Consensus Conference on Acute GVHD Grading).</description>
          <population>The number of intention-to-treat patients is 206. The incidence of aGVHD analysis is based on intention-to-treat (ITT) patients .</population>
          <units>percentage of partipants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.88" lower_limit="20.2" upper_limit="43.3"/>
                    <measurement group_id="O2" value="24.64" lower_limit="15.1" upper_limit="36.5"/>
                    <measurement group_id="O3" value="21.74" lower_limit="12.7" upper_limit="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidences of Invasive Fungal Diseases (IFD)</title>
        <description>The incidence of proven and probable Invasive fungal diseases (IFD) within 100 days post transplantation</description>
        <time_frame>100 day post transplant</time_frame>
        <population>The number of intention-to-treat patients is 206. The incidence of invasive fungal infection analysis within 100 day is based on intention-to-treat (ITT)patients .</population>
        <group_list>
          <group group_id="O1">
            <title>rhGM-CSF Group</title>
            <description>subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] &gt; 1.5×10(9)/L for 2 consecutive days).</description>
          </group>
          <group group_id="O2">
            <title>rhG-CSF+ rhGM-CSF</title>
            <description>a combination of 2-3μg/kg/d rhGM-CSF and 2-3μg/kg/d rhG-CSF each after transplantation, started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] &gt; 1.5×10(9)/L for 2 consecutive days).</description>
          </group>
          <group group_id="O3">
            <title>rhG-CSF Group</title>
            <description>subcutaneous rhG-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] &gt; 1.5×10(9)/L for 2 consecutive days).</description>
          </group>
        </group_list>
        <measure>
          <title>Incidences of Invasive Fungal Diseases (IFD)</title>
          <description>The incidence of proven and probable Invasive fungal diseases (IFD) within 100 days post transplantation</description>
          <population>The number of intention-to-treat patients is 206. The incidence of invasive fungal infection analysis within 100 day is based on intention-to-treat (ITT)patients .</population>
          <units>percentage of partipants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.76"/>
                    <measurement group_id="O2" value="10.14"/>
                    <measurement group_id="O3" value="23.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IFD Related Mortality</title>
        <description>IFD-related mortalities after a median follow-up of 600 days.</description>
        <time_frame>3-1099 days</time_frame>
        <population>The number of intention-to-treat patients is 206. The IFD related mortality analysis is based on intention-to-treat (ITT) patients .</population>
        <group_list>
          <group group_id="O1">
            <title>rhGM-CSF Group</title>
            <description>subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] &gt; 1.5×10(9)/L for 2 consecutive days).</description>
          </group>
          <group group_id="O2">
            <title>rhGM-CSF+ rhG-CSF Group</title>
            <description>a combination of 2-3μg/kg/d rhGM-CSF and 2-3μg/kg/d rhG-CSF each after transplantation, started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] &gt; 1.5×10(9)/L for 2 consecutive days).</description>
          </group>
          <group group_id="O3">
            <title>rhG-CSFgroup</title>
            <description>subcutaneous rhG-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] &gt; 1.5×10(9)/L for 2 consecutive days).</description>
          </group>
        </group_list>
        <measure>
          <title>IFD Related Mortality</title>
          <description>IFD-related mortalities after a median follow-up of 600 days.</description>
          <population>The number of intention-to-treat patients is 206. The IFD related mortality analysis is based on intention-to-treat (ITT) patients .</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" lower_limit="0.04" upper_limit="7.92"/>
                    <measurement group_id="O2" value="1.45" lower_limit="0.04" upper_limit="7.81"/>
                    <measurement group_id="O3" value="11.59" lower_limit="5.14" upper_limit="21.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relapse Related Mortality</title>
        <description>Relapse related mortality after a median follow-up of 600 days.</description>
        <time_frame>3～1099 days</time_frame>
        <population>The number of intention-to-treat patients is 206. The IFD related mortality analysis is based on intention-to-treat (ITT) patients .</population>
        <group_list>
          <group group_id="O1">
            <title>rhGM-CSF Group</title>
            <description>subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] &gt; 1.5×10(9)/L for 2 consecutive days).</description>
          </group>
          <group group_id="O2">
            <title>rhGM-CSF+ rhG-CSF Group</title>
            <description>a combination of 2-3μg/kg/d rhGM-CSF and 2-3μg/kg/d rhG-CSF each after transplantation, started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] &gt; 1.5×10(9)/L for 2 consecutive days).</description>
          </group>
          <group group_id="O3">
            <title>rhG-CSFgroup</title>
            <description>subcutaneous rhG-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] &gt; 1.5×10(9)/L for 2 consecutive days).</description>
          </group>
        </group_list>
        <measure>
          <title>Relapse Related Mortality</title>
          <description>Relapse related mortality after a median follow-up of 600 days.</description>
          <population>The number of intention-to-treat patients is 206. The IFD related mortality analysis is based on intention-to-treat (ITT) patients .</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8"/>
                    <measurement group_id="O2" value="8.7"/>
                    <measurement group_id="O3" value="4.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Graft Versus Host Disease (aGVHD) Related Mortality</title>
        <description>Graft versus host disease (aGVHD) related mortality after a median follow-up of 600 days .</description>
        <time_frame>3-1099 days</time_frame>
        <population>The number of intention-to-treat patients is 206. The IFD related mortality analysis is based on intention-to-treat (ITT) patients .</population>
        <group_list>
          <group group_id="O1">
            <title>rhGM-CSF Group</title>
            <description>subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] &gt; 1.5×10(9)/L for 2 consecutive days).</description>
          </group>
          <group group_id="O2">
            <title>rhGM-CSF+ rhG-CSF Group</title>
            <description>a combination of 2-3μg/kg/d rhGM-CSF and 2-3μg/kg/d rhG-CSF each after transplantation, started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] &gt; 1.5×10(9)/L for 2 consecutive days).</description>
          </group>
          <group group_id="O3">
            <title>rhG-CSFgroup</title>
            <description>subcutaneous rhG-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] &gt; 1.5×10(9)/L for 2 consecutive days).</description>
          </group>
        </group_list>
        <measure>
          <title>Graft Versus Host Disease (aGVHD) Related Mortality</title>
          <description>Graft versus host disease (aGVHD) related mortality after a median follow-up of 600 days .</description>
          <population>The number of intention-to-treat patients is 206. The IFD related mortality analysis is based on intention-to-treat (ITT) patients .</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.82"/>
                    <measurement group_id="O2" value="4.35"/>
                    <measurement group_id="O3" value="7.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemorrhage Related Mortality</title>
        <description>Hemorrhage related mortality after a median follow-up of 600 days</description>
        <time_frame>3-1099 days</time_frame>
        <population>The number of intention-to-treat patients is 206. The IFD related mortality analysis is based on intention-to-treat (ITT) patients .</population>
        <group_list>
          <group group_id="O1">
            <title>rhGM-CSF Group</title>
            <description>subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] &gt; 1.5×10(9)/L for 2 consecutive days).</description>
          </group>
          <group group_id="O2">
            <title>rhGM-CSF+ rhG-CSF Group</title>
            <description>a combination of 2-3μg/kg/d rhGM-CSF and 2-3μg/kg/d rhG-CSF each after transplantation, started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] &gt; 1.5×10(9)/L for 2 consecutive days).</description>
          </group>
          <group group_id="O3">
            <title>rhG-CSFgroup</title>
            <description>subcutaneous rhG-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] &gt; 1.5×10(9)/L for 2 consecutive days).</description>
          </group>
        </group_list>
        <measure>
          <title>Hemorrhage Related Mortality</title>
          <description>Hemorrhage related mortality after a median follow-up of 600 days</description>
          <population>The number of intention-to-treat patients is 206. The IFD related mortality analysis is based on intention-to-treat (ITT) patients .</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.88"/>
                    <measurement group_id="O2" value="1.45"/>
                    <measurement group_id="O3" value="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infection Related Mortality</title>
        <description>Infection related mortality after a median follow-up of 600 days.</description>
        <time_frame>3～1099 days)</time_frame>
        <population>The number of intention-to-treat patients is 206. The IFD related mortality analysis is based on intention-to-treat (ITT) patients .</population>
        <group_list>
          <group group_id="O1">
            <title>rhGM-CSF Group</title>
            <description>subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] &gt; 1.5×10(9)/L for 2 consecutive days).</description>
          </group>
          <group group_id="O2">
            <title>rhGM-CSF+ rhG-CSF Group</title>
            <description>a combination of 2-3μg/kg/d rhGM-CSF and 2-3μg/kg/d rhG-CSF each after transplantation, started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] &gt; 1.5×10(9)/L for 2 consecutive days).</description>
          </group>
          <group group_id="O3">
            <title>rhG-CSFgroup</title>
            <description>subcutaneous rhG-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] &gt; 1.5×10(9)/L for 2 consecutive days).</description>
          </group>
        </group_list>
        <measure>
          <title>Infection Related Mortality</title>
          <description>Infection related mortality after a median follow-up of 600 days.</description>
          <population>The number of intention-to-treat patients is 206. The IFD related mortality analysis is based on intention-to-treat (ITT) patients .</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47"/>
                    <measurement group_id="O2" value="5.8"/>
                    <measurement group_id="O3" value="14.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 days post transplant</time_frame>
      <group_list>
        <group group_id="E1">
          <title>rhGM-CSF Group</title>
          <description>subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] &gt; 1.5×10(9)/L for 2 consecutive days).</description>
        </group>
        <group group_id="E2">
          <title>rhG-CSF + rhGM-CSF Group</title>
          <description>a combination of 2-3μg/kg/d rhGM-CSF and 2-3μg/kg/d rhG-CSF each after transplantation, started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] &gt; 1.5×10(9)/L for 2 consecutive days).</description>
        </group>
        <group group_id="E3">
          <title>rhG-CSF Group</title>
          <description>subcutaneous rhG-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] &gt; 1.5×10(9)/L for 2 consecutive days).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The limitations of the current study included the lack of blinding and placebo group.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chun Wang</name_or_title>
      <organization>Department of Hematology, Shanghai Jiao Tong University Affiliated First People’s Hospital, China</organization>
      <email>wangchun2@medmail.com.cn</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

